Profile cover photo
Profile photo
LDNNow
31 followers -
Naltrexone, autoimmune, cancer, CNS disorders, biotherapy, met enkephalin, OGF, OGFreceptor, TLR4
Naltrexone, autoimmune, cancer, CNS disorders, biotherapy, met enkephalin, OGF, OGFreceptor, TLR4

31 followers
About
Posts

Post has attachment
Public
Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds:-
Results: Wound closure rates with topical NTX in type 1 diabetic rats were comparable to Regranex. Topical NTX accelerated DNA synthesis, as measured by BrdU incorporation, increased mast cells, and enhanced expression of platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), a marker for angiogenesis. Regranex had little effect on DNA synthesis, mast cells, and VEGF expression relative to vehicle-treated wounds, and it only temporarily increased PDGF expression. Fibroblast growth factor expression was not altered by either treatment.
https://www.facebook.com/notes/ldnnow/topical-naltrexone-is-a-safe-and-effective-alternative-to-standard-treatment-of-/10155239177753391/
Add a comment...

Post has attachment
Public
Psychoneuroimmunological approach to gastrointestinal related pain:
Rather than proceeding with established allopathic single-target central or peripheral treatments, by non-invasively modulating the brain–gut axis components such as the psychological and neuroendocrinological status, microbiota, enteric nervous system, or immune cells (e.g. glial or mast cells), a favourable clinical outcome in various chronic gastrointestinal related pain syndromes may be achieved. Clinical tools are readily available in forms of psychotherapy, prebiotics, probiotics, nutritional advice, and off-label drugs. An example of the latter is low-dose naltrexone, a compound which opens the perspective of targeting glial cells to reduce neuroinflammation and ultimately pain.
https://www.facebook.com/notes/ldnnow/psychoneuroimmunological-approach-to-gastrointestinal-related-pain/10155223375648391/
Add a comment...

Post has attachment
Successful Treatment of Adult-Onset Dermatitis Herpetiformis with Low Dose Naltrexone - A Case Study
Dr Leonard Weinstock writes up a case study with a celiac disease patient with diet refractory dermatitis herpetiformis who was treated with LDN. The patient’s skin lesions were present for 2 years and went into complete remission within 3 months of taking LDN.
https://www.facebook.com/notes/ldnnow/successful-treatment-of-adult-onset-dermatitis-herpetiformis-with-low-dose-naltr/10155069346058391/
Add a comment...

Post has attachment
Low-dose Naltrexone for the treatment of sarcoidosis:-

Naltrexone 1 mg/day was started in early February 2015. Two months later, she reported less fatigue and dyspnea and was able to stop using inhalers and minocycline without relapse of the rash. The naltrexone dose was increased over 12 days to 4.5 mg in an attempt to prevent recurrent parotitis. Two months later, she reported further improvement in dyspnea and more energy although she had another bout of parotitis. Five months after starting LDN the CT showed reduction in the size of the splenic and the liver lesions with stability of periportal lymph nodes (Fig. 1C, 2C). Twelve months after starting LDN, she has maintained improvement in energy and prevention of the skin rash. The CT showed complete improvement in the splenic and liver lesions (Fig. 1D; 2D). Pulmonary function tests were unchanged after 5 months of the LDN.

https://www.facebook.com/notes/ldnnow/low-dose-naltrexone-for-the-treatment-of-sarcoidosis/10155032472528391/
Add a comment...

Post has attachment
An Immune Disease? Low Dose Naltrexone (LDN) Fibromyalgia Study Suggests FM Has Inflammatory Side
“People with fibromyalgia don't experience the redness, swelling and tissue damage seen in inflammatory disorders like arthritis but that doesn't necessarily mean that the mighty immune system isn't involved.
Jarred Younger believes FM is an immune disorder of the brain. His low dose naltrexone (LDN) study suggests the immune system may indeed play a significant role in fibromyalgia. If that's true a significant shift in how FM is approached will be needed.” - Health Rising
https://www.facebook.com/notes/ldnnow/an-immune-disease-low-dose-naltrexone-ldn-fibromyalgia-study-suggests-fm-has-inf/10154885233753391/
Add a comment...

Post has attachment
Drug that helps addicts may help treat cancer too, say experts:
Scientists at St George's, University of London, say the drug naltrexone (LDN), which is used to treat addicts, can have a beneficial impact on cancer patients if it is given in low doses.
Researchers discovered that not only does LDN cause cancer cells to stop growing, it also alters their internal machinery, making them more likely to kill themselves. This can lead to other treatments becoming more effective.
https://www.facebook.com/notes/ldnnow/drug-that-helps-addicts-may-help-treat-cancer-too-say-experts/10154938348563391/
Add a comment...

Post has attachment

Post has attachment
Add a comment...

Post has attachment
Innovative Alternative Therapies for Chronic Lyme Disease

Kent Holdorf MD shares his findings, views and thoughts in a presentation on Lyme Disease at the AARM Regional Conference, Overcoming Diagnostic and Treatment Challenges of Lyme Disease, Infectious Diseases and CSF, Seattle, Washington, 2017.

In an open-label study by Horowitz of 1000+ patients with Lyme disease and MSIDS, approximately 75% of patients experienced less fatigue, myalgia, and arthralgia when the naltrexone dose was titrated to 4.5 mg at bedtime

Lyme disease/CFS/FM are multisystem diseases with a key component being immune dysfunction. Being able to identify and treat the immune dysfunction (TH1-TH2 shift) that is consistently seen with these illnesses can improve diagnostic accuracy, result in significant symptomatic improvement and significantly increase the likelihood of successful longterm success. Multisystem treatments that address the underlying multisystem abnormalities, including LDN, peptide therapies, T3, cortisol, sargramostim/filgrastim, ozone and low dose heparin can be very effective for non-responsive patients

https://restorativemedicine.org/wp-content/uploads/2017/01/4Holtorf_-Lyme-CFS.pdf
Add a comment...

Post has attachment
LDN clinical trial - Immune Effects of Low-dose Naltrexone in ME/CFS

This study that is being conducted by Dr Jarred Younger at University of Alabama is currently recruiting participants (18-65 year olds).
The main objective of this study is to test if naltrexone, when taken in low doses, has an anti-inflammatory effect that may be associated with positive clinical outcomes in people with chronic fatigue syndrome (CFS). In part, the present study, is a continuation of prior work in which we showed that chronic fatigue symptoms are associated with immune activity, and that low-dose naltrexone might exert anti-inflammatory effects in fibromyalgia, which is thought to share some pathophysiological and clinical characteristics with CFS.

https://clinicaltrials.gov/ct2/show/study/NCT02965768#contacts
Add a comment...
Wait while more posts are being loaded